Your browser is no longer supported. Please, upgrade your browser.
GALT Galectin Therapeutics, Inc. monthly Stock Chart
GALT [NASD]
Galectin Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.56 Insider Own2.70% Shs Outstand36.26M Perf Week-3.29%
Market Cap85.21M Forward P/E- EPS next Y-0.48 Insider Trans1.60% Shs Float28.16M Perf Month-18.12%
Income-18.60M PEG- EPS next Q-0.11 Inst Own10.80% Short Float4.58% Perf Quarter39.88%
Sales- P/S- EPS this Y12.70% Inst Trans-2.30% Short Ratio2.21 Perf Half Y-1.26%
Book/sh-0.18 P/B- EPS next Y9.40% ROA-160.90% Target Price5.33 Perf Year164.04%
Cash/sh0.19 P/C12.17 EPS next 5Y- ROE- 52W Range0.88 - 3.68 Perf YTD139.84%
Dividend- P/FCF- EPS past 5Y6.30% ROI- 52W High-36.14% Beta2.57
Dividend %- Quick Ratio1.60 Sales past 5Y- Gross Margin- 52W Low167.05% ATR0.34
Employees7 Current Ratio1.60 Sales Q/Q- Oper. Margin- RSI (14)47.78 Volatility11.40% 15.74%
OptionableYes Debt/Eq- EPS Q/Q16.40% Profit Margin- Rel Volume0.82 Prev Close2.39
ShortableNo LT Debt/Eq- EarningsNov 14 BMO Payout- Avg Volume584.66K Price2.35
Recom2.00 SMA20-5.14% SMA50-7.17% SMA2000.41% Volume478,760 Change-1.67%
Dec-07-17Reiterated H.C. Wainwright Buy $6 → $10
Nov-28-17Reiterated H.C. Wainwright Buy $3.50 → $6
Oct-19-17Initiated ROTH Capital Buy
Mar-30-17Upgrade H.C. Wainwright Neutral → Buy $3.50
Oct-03-16Downgrade FBR & Co. Outperform → Mkt Perform $12 → $2
Sep-29-16Downgrade H.C. Wainwright Buy → Neutral $1.50
Sep-28-16Downgrade ROTH Capital Buy → Sell
Mar-28-16Resumed H.C. Wainwright Buy $8
Sep-21-15Initiated H.C. Wainwright Buy $7
Aug-01-14Downgrade Aegis Capital Buy → Hold
Jul-30-14Reiterated MLV & Co Buy $27 → $16
Jul-29-14Reiterated MLV & Co Buy $27 → $15
Apr-02-14Reiterated MLV & Co Buy $20 → $27
Feb-10-14Reiterated Aegis Capital Buy $16 → $32
Jan-09-14Reiterated Aegis Capital Buy $10 → $16
Dec-03-13Initiated MLV & Co Buy $20
Aug-19-13Reiterated Aegis Capital Buy $7 → $10
Dec-14-17 09:30AM  Galectin Therapeutics Provides Corporate Update at Annual Meeting GlobeNewswire
Dec-11-17 09:00AM  Galectin Therapeutics to Webcast Corporate Update at Annual Meeting of Shareholders GlobeNewswire
Dec-06-17 08:00AM  Todays Research Reports on Stocks to Watch: Allergan plc and Galectin Therapeutics ACCESSWIRE -10.47%
Dec-05-17 02:29PM  Galectin Therapeutics Inc Goes Down Swinging Following Phase 2b NASH Trial Failure SmarterAnalyst -30.65%
10:08AM  Galectin slumps after NASH drug misses main goal of mid-stage trial Reuters
08:59AM  Galectin Therapeutics stock drops nearly 50% after negative trial results MarketWatch
08:15AM  Galectin Therapeutics Announces Results from Phase 2b NASH-CX Trial GlobeNewswire
08:15AM  Galectin says NASH drug misses main goal of midstage trial Reuters
Dec-04-17 04:00PM  Galectin Therapeutics to Present Results from Phase 2b NASH-CX Trial on December 5, 2017 GlobeNewswire
Dec-01-17 08:48AM  Implied Volatility Surging for Galectin Therapeutics (GALT) Stock Options Zacks
08:30AM  Factors of Influence in 2018, Key Indicators and Opportunity within Xilinx, J.B. Hunt Transport Services, Southern, FirstEnergy, AMAG Pharmaceuticals, and Galectin Therapeutics New Research Emphasizes Economic Growth GlobeNewswire
Nov-13-17 09:00AM  Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Anti-Fibrotic Drug Development Summit 2017 GlobeNewswire +7.14%
08:30AM  Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical Trial GlobeNewswire
Nov-07-17 08:15AM  Galectin Therapeutics Reports 2017 Third Quarter Financial Results and Provides Business Update GlobeNewswire +7.44%
Oct-20-17 08:30AM  Galectin Therapeutics to Present Clinical Data at The Liver Meeting® 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH Cirrhosis GlobeNewswire +6.83%
Oct-11-17 08:57AM  Galectin Therapeutics (GALT) in Focus: Stock Moves 6.5% Higher Zacks
Sep-25-17 08:30AM  Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Conference for NASH Summit Europe 2017 GlobeNewswire +6.81%
Sep-12-17 08:30AM  Galectin Therapeutics Receives Notice of Chinese Allowance to Grant a Key Patent for Composition of Matter for GR-MD-02 GlobeNewswire
Sep-05-17 08:30AM  Galectin Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference GlobeNewswire
Aug-28-17 07:50AM  Earnings Review and Free Research Report: Zoetis Results Beat Estimates in EPS and Revenues; Updated Full Year Guidance ACCESSWIRE
Aug-18-17 08:30AM  Clarification: Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update GlobeNewswire
Aug-14-17 08:15AM  Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update GlobeNewswire +6.40%
Jul-25-17 08:30AM  Patent for Enhancing Immunotherapy in Cancer Treatment Granted to Galectin Therapeutics GlobeNewswire +6.76%
Jul-07-17 12:00PM  Galectin Therapeutics to Present at the Singular Research Summer Conference GlobeNewswire
Jun-29-17 09:02AM  Ammo, Inc. Appoints Two Senior Executives to Board of Directors GlobeNewswire
Jun-23-17 07:00AM  [$$] Drug Companies Seek to Raise Awareness of Liver Ailment The Wall Street Journal
Jun-21-17 08:30AM  Patent for Reducing Inflammatory Response Granted to Galectin Therapeutics GlobeNewswire
Jun-13-17 08:30AM  Galectin Therapeutics Announces Important Milestones towards Completion of NASH CX Trial GlobeNewswire
Jun-06-17 08:30AM  Autoimmune Disease Patent Granted to Galectin Therapeutics GlobeNewswire
May-15-17 08:30AM  Galectin Therapeutics Reports 2017 First Quarter Financial Results and Provides Business Update GlobeNewswire
May-03-17 08:30AM  Galectin Therapeutics launches the Liver Line, an online community and publication on liver health and liver disease GlobeNewswire
Apr-28-17 07:36AM  Can The Uptrend Continue for Galectin Therapeutics (GALT)? Zacks
Apr-25-17 08:00AM  Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02 GlobeNewswire
Apr-24-17 08:59AM  Will Henry Schein (HSIC) Deliver a Surprise in Q1 Earnings? Zacks
08:53AM  Can Myriad Genetics (MYGN) Spring a Surprise in Q3 Earnings? Zacks
Apr-20-17 09:08AM  Edward Lifesciences (EW) Q1 Earnings: A Surprise in Store? Zacks
08:49AM  Can Mead Johnson (MJN) Spring a Surprise in Q1 Earnings? Zacks
Apr-18-17 09:27AM  ResMed (RMD) Q3 Earnings: Disappointment in the Cards? Zacks
09:10AM  IDEXX Laboratories (IDXX) Q1 Earnings: Surprise in Store? Zacks
08:00AM  Galectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congress 2017 GlobeNewswire
Apr-17-17 09:32AM  Can Illumina (ILMN) Spring a Surprise this Earnings Season? Zacks
09:20AM  5 Drug Stocks That Could Be Big Winners this Earnings Season Zacks
Apr-13-17 10:05AM  Integra LifeSciences (IART) Q1 Earnings: A Beat in Store? Zacks
Apr-12-17 09:06AM  GNC Holdings (GNC) Q1 Earnings: Disappointment in Store? Zacks
Apr-11-17 07:30AM  Galectin Therapeutics and Axovant Sciences See Stocks Rise on Investor Optimism Accesswire +5.92%
Apr-10-17 08:20AM  Galectin Therapeutics (GALT) Looks Good: Stock Jumps 16.7% Zacks +5.92%
Apr-07-17 06:17AM  Can The Uptrend Continue for Galectin Therapeutics (GALT)? Zacks +16.67%
Apr-03-17 09:30AM  Akari Therapeutics, Galectin Therapeutics Receive Positive Financial News Accesswire -5.22%
Mar-31-17 01:04PM  GALECTIN THERAPEUTICS INC Financials +13.30%
Mar-30-17 08:46AM  Galectin Shares Upgraded To Buy; NASH-CX Results In December A 'Major Stock Catalyst' Benzinga
07:12AM  Galectin Therapeutics upgraded by H.C. Wainwright
Mar-29-17 09:00AM  Edited Transcript of GALT earnings conference call or presentation 28-Mar-17 1:00pm GMT Thomson Reuters StreetEvents
Mar-28-17 09:00AM  Galectin Therapeutics Inc Earnings Call scheduled for 9:00 am ET today -12.88%
08:30AM  Galectin Therapeutics Reports 2016 Financial Results and Provides Business Update GlobeNewswire
08:22AM  GALECTIN THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
08:19AM  GALECTIN THERAPEUTICS INC Files SEC form 10-K, Annual Report
07:07AM  Q4 2016 Galectin Therapeutics Inc Earnings Release - Before Market Open
Mar-23-17 08:30AM  Galectin Therapeutics Issues Statement Regarding GALTW and GALTU GlobeNewswire
Mar-21-17 08:30AM  Galectin Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update GlobeNewswire
Mar-15-17 09:30AM  Galectin Therapeutics and Aratana Therapeutics Look Forward to the 4th Quarter of 2017 Accesswire
Mar-14-17 08:47AM  GR-MD-02 Demonstrates Clinically Significant Effect in Patients with Severe and Refractory Atopic Dermatitis (Eczema) GlobeNewswire
08:23AM  GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Mar-09-17 08:30AM  Galectin Therapeutics to Present at 29th Annual ROTH Conference GlobeNewswire
Mar-06-17 08:30AM  Galectins GR-MD-02 Demonstrates Efficacy in Patients with Moderate to Severe Plaque Psoriasis GlobeNewswire
Feb-22-17 09:30AM  Bull Market Ahead for the Biotech Industry in 2017? Today's Reports on Sarepta Therapeutics and Galectin Therapeutics Accesswire -11.86%
Feb-17-17 04:34PM  GALECTIN THERAPEUTICS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financ
Feb-08-17 08:30AM  Galectin Therapeutics to Present at BIO CEO & Investor Conference GlobeNewswire -7.87%
Feb-07-17 04:40PM  GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +10.43%
04:40PM  Combination Immunotherapy with Galectin-3 Inhibitor GR-MD-02 Enhances Effects in Pre-clinical Models and Early Results of Phase 1 Clinical Trials GlobeNewswire
Feb-06-17 08:30AM  Galectin Therapeutics Presentation Now Available for On-Demand Viewing PR Newswire +10.58%
Feb-02-17 11:06AM  GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Feb-01-17 08:10AM  Galectin Therapeutics Announces Achievement of Key Milestones Related to NASH-CX Clinical Trial GlobeNewswire
08:02AM  GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jan-30-17 02:16PM  Life Sciences & Healthcare Investor Conference & Webinar: Nasdaq and OTCQX Companies Present February 2nd PR Newswire
08:30AM  Galectin Therapeutics to Webcast, Live, at VirtualInvestorConferences.com on February 2 PR Newswire
Dec-29-16 09:00AM  Galectin Therapeutics Announces $4 Million in New Equity Financings GlobeNewswire
08:57AM  GALECTIN THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity
Dec-20-16 08:01AM  GALECTIN THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders +11.14%
Dec-08-16 08:00AM  Galectin Therapeutics to Webcast Corporate Update At Annual Meeting of Stockholders GlobeNewswire +7.93%
Nov-11-16 01:40PM  Galectin Buoyed By Plaque Psoriasis Study (GALT) at Investopedia +17.42%
Nov-10-16 08:00AM  GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +23.02%
08:00AM  Galectin Therapeutics Announces Positive New Psoriasis and Atopic Dermatitis Clinical Data, Seeking Strategic Partnerships for Therapy of Severe Skin Diseases GlobeNewswire
Nov-08-16 08:00AM  Galectin Therapeutics Reports Third Quarter 2016 Financial Results and Provides Business Update GlobeNewswire +15.24%
07:56AM  GALECTIN THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
07:52AM  GALECTIN THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report
Oct-31-16 11:15AM  Research Reports Coverage on Generic Drugs Stocks -- Evoke Pharma, Catalyst Pharma, Neurocrine Biosciences, and Galectin Therapeutics PR Newswire
Oct-17-16 08:30AM  Galectin Therapeutics to Webcast Corporate Presentation at the MicroCap Conference on October 25 in Philadelphia GlobeNewswire
Oct-11-16 11:49AM  Galectin Therapeutics, Inc. to Present at The MicroCap Conference on October 24-25 in Philadelphia Accesswire
Oct-07-16 08:30AM  Galectin Therapeutics to Present Clinical Data on Selective Non-Invasive Tests for the Development of Novel Therapies for Nonalcoholic Steatohepatitis GlobeNewswire -6.09%
Sep-29-16 04:05PM  Galectin Tanks on Failure of NASH Treatment (GALT) at Investopedia -12.86%
02:13PM  Galectin Therapeutics (GALT) Stock Drops on Drug Failure, Downgraded
Sep-28-16 10:59AM  Galectin Therapeutics (GALT) Stock Declines on Drug Failure, Rating Cut -43.32%
10:15AM  Why Traders Are Talking About Origin Agritech, Galectin, Avis, Hertz, and More at Insider Monkey
Sep-27-16 04:15PM  Galectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot Trial (NASH-FX) with GR-MD-02 in NASH Patients with Advanced Fibrosis GlobeNewswire
04:12PM  GALECTIN THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity
Sep-23-16 10:34AM  Can The Uptrend Continue for Galectin Therapeutics (GALT)?
Sep-22-16 09:08AM  5 Biotech Stocks to Watch as Interest in NASH Increases +10.38%
05:53AM  Is Galectin The Next Takeover Target for the Biotech World?
Sep-20-16 01:02PM  NASH Hype Has These 2 Stocks Soaring, Plus the Latest On MGT Capital, PTC Therapeutics, and Cloud Peak Energy at Insider Monkey +14.84%
Aug-31-16 08:00AM  Galectin Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference GlobeNewswire
Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its collaborative joint venture, Galectin Sciences, LLC with SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rubin MarcDirectorDec 08Buy1.857,00012,97255,581Dec 08 02:26 PM
FREEMAN KEVIN DDirectorDec 07Buy1.638,00013,0058,000Dec 08 02:26 PM
FREEMAN KEVIN DDirectorDec 07Buy1.6440065728,043Dec 08 02:26 PM
ZUCCONI THEODORE DANIELDirectorMay 23Buy2.271,0002,2701,083May 24 09:39 AM
10X Fund, L.P.10% OwnerJan 27Option Exercise3.0055,834167,5022,629,519Jan 29 05:07 PM